BACKGROUND: The Airways Questionnaire 20 (AQ20) is a concise measure of health-related quality of life (HRQL) in obstructive airway disease; however, its original format may underestimate impairment due to the complete cessation of certain activities. METHODS: We revised seven items of the original AQ20 (revised AQ20 [AQ20-R]), adding response options for inability to perform certain activities. We assessed the performance of the AQ20-R among 352 adults with various airway conditions identified through a random telephone sample. Concurrent validity of the AQ20-R was assessed relative to the Short Form-12 (SF-12) physical component summary (PCS), FEV(1), and medication use. Predictive validity was assessed relative to health-care utilization among 278 subjects studied longitudinally. RESULTS: Twenty-one of 352 subjects were unable to perform at least one activity. These subjects demonstrated higher AQ20-R scores (p < 0.001) indicating worse HRQL. Mean (+/- SD) AQ20-R scores differed significantly (p < 0.001) among subjects with COPD (8.9 +/- 5.2), asthma (6.7 +/- 5.0), and chronic bronchitis (4.7 +/- 4.2). At baseline, the AQ20-R correlated with the SF-12 PCS (r = - 0.55, p < 0.001) and FEV(1) (r = - 0.43, p < 0.001), and was associated with the use of respiratory-specific therapies (p </= 0.001). In multivariate models, the AQ20-R was an independent predictor of outpatient visits (odds ratio, 2.2; 95% confidence interval, 1.6 to 3.1), emergency department visits (odds ratio, 2.9; 95% confidence interval, 1.9 to 4.6), hospitalization (odds ratio, 2.8; 95% confidence interval, 1.6 to 4.9), and ICU admission (odds ratio, 3.0; 95% confidence interval, 1.2 to 7.3) during the following year. CONCLUSIONS: The AQ20-R is a valid respiratory-specific HRQL measure that accounts for activity cessation among the most impaired and can be used across various airway conditions.
BACKGROUND: The Airways Questionnaire 20 (AQ20) is a concise measure of health-related quality of life (HRQL) in obstructive airway disease; however, its original format may underestimate impairment due to the complete cessation of certain activities. METHODS: We revised seven items of the original AQ20 (revised AQ20 [AQ20-R]), adding response options for inability to perform certain activities. We assessed the performance of the AQ20-R among 352 adults with various airway conditions identified through a random telephone sample. Concurrent validity of the AQ20-R was assessed relative to the Short Form-12 (SF-12) physical component summary (PCS), FEV(1), and medication use. Predictive validity was assessed relative to health-care utilization among 278 subjects studied longitudinally. RESULTS: Twenty-one of 352 subjects were unable to perform at least one activity. These subjects demonstrated higher AQ20-R scores (p < 0.001) indicating worse HRQL. Mean (+/- SD) AQ20-R scores differed significantly (p < 0.001) among subjects with COPD (8.9 +/- 5.2), asthma (6.7 +/- 5.0), and chronic bronchitis (4.7 +/- 4.2). At baseline, the AQ20-R correlated with the SF-12 PCS (r = - 0.55, p < 0.001) and FEV(1) (r = - 0.43, p < 0.001), and was associated with the use of respiratory-specific therapies (p </= 0.001). In multivariate models, the AQ20-R was an independent predictor of outpatient visits (odds ratio, 2.2; 95% confidence interval, 1.6 to 3.1), emergency department visits (odds ratio, 2.9; 95% confidence interval, 1.9 to 4.6), hospitalization (odds ratio, 2.8; 95% confidence interval, 1.6 to 4.9), and ICU admission (odds ratio, 3.0; 95% confidence interval, 1.2 to 7.3) during the following year. CONCLUSIONS: The AQ20-R is a valid respiratory-specific HRQL measure that accounts for activity cessation among the most impaired and can be used across various airway conditions.
Authors: Mark D Eisner; Paul D Blanc; Edward H Yelin; Patricia P Katz; Gabriela Sanchez; Carlos Iribarren; Theodore A Omachi Journal: Thorax Date: 2010-03 Impact factor: 9.139
Authors: Mark D Eisner; Theodore A Omachi; Patricia P Katz; Edward H Yelin; Carlos Iribarren; Paul D Blanc Journal: Chest Date: 2009-12-29 Impact factor: 9.410
Authors: J P Singer; P P Katz; A Soong; P Shrestha; D Huang; J Ho; M Mindo; J R Greenland; S R Hays; J Golden; J Kukreja; M E Kleinhenz; R J Shah; P D Blanc Journal: Am J Transplant Date: 2017-01-03 Impact factor: 8.086
Authors: Theodore A Omachi; Urmimala Sarkar; Edward H Yelin; Paul D Blanc; Patricia P Katz Journal: J Gen Intern Med Date: 2012-08-14 Impact factor: 5.128
Authors: Nicholas A Kolaitis; Allison Soong; Pavan Shrestha; Hanjing Zhuo; John Neuhaus; Patti P Katz; John R Greenland; Jeffrey Golden; Lorriana E Leard; Rupal J Shah; Steven R Hays; Jasleen Kukreja; Mary Ellen Kleinhenz; Paul D Blanc; Jonathan P Singer Journal: J Thorac Cardiovasc Surg Date: 2018-02-22 Impact factor: 5.209
Authors: Theodore A Omachi; Patricia P Katz; Edward H Yelin; Carlos Iribarren; Sara J Knight; Paul D Blanc; Mark D Eisner Journal: Chest Date: 2009-10-16 Impact factor: 9.410
Authors: Theodore A Omachi; Patricia P Katz; Edward H Yelin; Steven E Gregorich; Carlos Iribarren; Paul D Blanc; Mark D Eisner Journal: Am J Med Date: 2009-08 Impact factor: 4.965
Authors: Mark D Eisner; Carlos Iribarren; Edward H Yelin; Stephen Sidney; Patricia P Katz; Gabriela Sanchez; Paul D Blanc Journal: Int J Chron Obstruct Pulmon Dis Date: 2009-05-07